Drug Profile
Doxorubicin liposomal - Ambrilia Biopharma
Alternative Names: TVT-DoxLatest Information Update: 26 Jul 2013
Price :
$50
*
At a glance
- Originator Ambrilia Biopharma
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Jul 2013 Discontinued - Preclinical for Cancer in Canada (Injection) prior to 26 July 2013
- 07 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the Cancer pharmacodynamics section
- 03 Mar 2006 Cellpep has merged with Procyon Biopharma to form Ambrilia Biopharma